Key Takeaways
- In November 2025, the FDA announced it would begin removing the boxed warning from menopausal hormone therapy products.
- In February 2026, the agency approved the first batch of updated labels — six products, with more still working through the process.
- Risk statements about cardiovascular disease, breast cancer, and probable dementia were removed from the boxed warning specifically — not from the label entirely.
- The change is to how risk is communicated. It is not a statement that hormone therapy is right for every patient.
Since late 2025, one of the most recognizable warnings in women’s medicine has been coming off the label.
For more than twenty years, menopausal hormone therapy products carried a boxed warning — the FDA’s most prominent safety notice — describing risks including stroke, blood clots, dementia, and breast cancer. That warning shaped how two generations of women were counseled about menopause, and how many of them decided against treatment entirely.
The FDA has now begun removing it. But the change is narrower and slower than most coverage has suggested, and understanding the difference matters if you are trying to decide what it means for you.
What did the FDA actually announce?
On November 10, 2025, the Department of Health and Human Services and the FDA announced the agency was initiating removal of the boxed warning from menopausal hormone therapy products. According to the FDA, the decision followed a comprehensive review of the scientific literature, an expert advisory panel held in July 2025, and a public comment period.
That November announcement was the starting point, not the finish line. Labels are held by the companies that make each product, and each one has to be revised and approved individually.
On February 12, 2026, the FDA announced it had approved labeling changes for six menopausal hormone therapy products. The agency noted that 29 drug companies had submitted proposed labeling changes at its request. Those first six products span the four categories of menopausal hormone therapy: systemic combination therapy, systemic estrogen-alone therapy, systemic progestogen-alone therapy for women with a uterus using systemic estrogen, and topical vaginal estrogen therapy.
So the accurate description as of today is not that the warning is gone. It is that the FDA began removing it in November 2025, the first approved labels appeared in February 2026, and the remaining products are still moving through the process.
What was removed, and what stayed?
This is the part that gets lost most often.
The FDA removed risk statements related to cardiovascular disease, breast cancer, and probable dementia from the boxed warning. Information about cardiovascular disease and breast cancer was retained in the labeling — it simply no longer sits inside the box.
That distinction is not a technicality. A boxed warning is a blanket signal applied to an entire class of drugs. Moving information out of the box changes how prominently that risk is presented; it does not erase the underlying data or mean the risk was found to be nonexistent.
Why now, after twenty years?
The boxed warning traces back to the Women’s Health Initiative, a large trial whose early-2000s findings linked one specific formulation of hormone therapy to increased risk. The results were widely publicized, and the warning was applied across the class — including to low-dose vaginal products, which deliver far less hormone into the bloodstream than systemic formulations.
In the years since, clinicians and professional societies argued the single class-wide warning was too blunt an instrument: it applied the same alarm to very different products, doses, and routes of administration, and to women at very different ages and stages. The FDA’s July 2025 advisory panel revisited that question, and the agency’s stated rationale for the labeling change points to evidence around timing — specifically, data on women who begin therapy within about ten years of menopause onset and before age 60.
What this does not mean
It does not mean hormone therapy is now considered risk-free. The FDA changed how risk information is presented; it did not declare the risks resolved.
It does not mean hormone therapy is appropriate for everyone. Personal and family history, age, time since menopause, the specific formulation, and the route of administration all still matter, and they still have to be weighed individually.
And it does not mean anyone should start, stop, or change a prescription based on a news story. If you were told years ago that hormone therapy was off the table for you, the labeling change is a legitimate reason to revisit that conversation with a licensed clinician — not a reason to skip it.
What to do with this information
If you are currently on hormone therapy, nothing about the labeling change requires you to do anything. Your prescription has not changed.
If you previously declined hormone therapy — or were steered away from it — because of the boxed warning, it is reasonable to ask your provider whether the updated labeling changes the risk-benefit picture in your particular case. Bring your history. The answer will depend on it.
If you are reading older patient education material, check the date. Anything written before November 2025 describes a labeling standard the FDA has since revised.
Sources
- FDA: HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy (November 10, 2025)
- FDA: FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (February 12, 2026)
- FDA: FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies
This article is provided for general educational purposes and is not medical advice. Hormone therapy decisions should be made with a licensed clinician who knows your history. Evolve Health & Wellness provides women’s hormone therapy in Saint Cloud, Florida, and via telehealth throughout Florida.
